Comparison tools
📊 Multi-Peptide Comparison Engine
Compare two to four peptides across listed targets, half-life, community-reported experience, risk context, and practical considerations.
Side-by-Side Comparison
Side-by-Side Peptide Comparison Matrix
Select 2 to 4 peptides to compare molecular targets, half-life, user satisfaction, onset speed, and dosage.
| Metric / Property | Tirzepatide Tirzepatide | Semaglutide Semaglutide | Retatrutide Retatrutide |
|---|---|---|---|
| Primary Targets | GLP-1R (Glucagon-Like Peptide-1 Receptor)GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor) | GLP-1R (Glucagon-Like Peptide-1 Receptor) | GLP-1RGIPRGCGR (Glucagon Receptor) |
| Half-Life (t½) | Approximately 5.0 days (120 hours, supporting once-weekly dosing) | Approximately 7.0 days (168 hours) | Approximately 6.0 days (144 hours, supporting once-weekly dosing) |
| Typical Dosage | 2.5mg - 15.0mg / week Once weekly SubQ injection (or split into twice weekly for sensitive users) | 0.25mg - 2.4mg / week Once weekly SubQ injection | 2.0mg - 12.0mg / week Once weekly SubQ injection (outer thigh preferred) |
| User Satisfaction | 97% | 91% | 98% |
| Onset Speed | Appetite drops sharply within 24-48 hours of first dose | Noticeable satiety boost in Week 1 | Accelerated visceral and hepatic lipid clearance |
| Injection Comfort (PIP) | PIP: 1 / 5 (SubQ injection is virtually painless) | PIP: 1 / 5 (SubQ injection is painless) | PIP: 1 / 5 (SubQ injection is painless) |
| Full Dossier → | Full Dossier → | Full Dossier → |